(WST) West Pharmaceutical - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US9553061055

Stoppers, Seals, Syringe Components, Vials, Self-Injection Devices

Health Care Supplies
Market Cap in USD: 19,801m

IPO / Inception: 1978-01-13
12m vs SPY: -33.5%

EPS (Earnings per Share)

EPS CAGR: -50.01%
EPS Trend: -58.4%

Last SUE: -4.00
Qual. Beats: 0

Revenue

Rev. CAGR: 2.66%
Rev. Trend: 31.6%

Last SUE: 0.72
Qual. Beats: 0

Dividends

Dividend Yield	0.33%
Yield on Cost 5y	0.36%
Yield CAGR 5y	5.35%
Payout Consistency	96.6%
Payout Ratio	12.2%

Risk via 5d forecast
Volatility	41.1%
Value at Risk 5%th	46.1%
Relative Tail Risk	-31.81%

Reward TTM
Sharpe Ratio	-0.15
Alpha	-31.16
CAGR/Max DD	0.05

Character TTM
Hurst Exponent	0.492
Beta	0.551
Beta Downside	0.471

Drawdowns 3y
Max DD	53.79%
Mean DD	21.41%
Median DD	20.10%

Description: WST West Pharmaceutical December 19, 2025

West Pharmaceutical Services (WST) designs, manufactures, and sells injectable drug containment and delivery systems worldwide, operating through two segments: Proprietary Products-offering stoppers, seals, syringe components, advanced reconstitution technologies, and integrated packaging services for biologic, generic, and pharma customers; and Contract-Manufactured Products-providing automated assembly of surgical, diagnostic, ophthalmic, and consumer drug-delivery devices for pharma and med-device firms. The company leverages a global sales force, distributors, and contract agents to serve markets across the Americas, Europe, the Middle East, Africa, and Asia-Pacific.

Key recent data points: FY 2023 revenue reached approximately $2.6 billion with an operating margin near 13%, reflecting strong demand for biologics packaging; the injectable device market is projected to grow at a 5-6% CAGR through 2029, driven by an expanding pipeline of biologic therapies and heightened regulatory focus on sterility and safety. Additionally, West’s investment in automation and polymer-based vial technologies (e.g., Crystal Zenith) positions it to capture cost-savings and sustainability trends valued by large pharma customers.

For a deeper dive into WST’s valuation metrics and peer comparison, you might find ValueRay’s analyst toolkit useful.

Piotroski VR‑10 (Strict, 0-10) 6.5

Net Income (491.7m TTM) > 0 and > 6% of Revenue (6% = 181.0m TTM)

FCFTA 0.09 (>2.0%) and ΔFCFTA 0.48pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 39.37% (prev 35.95%; Δ 3.42pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.17 (>3.0%) and CFO 693.8m > Net Income 491.7m (YES >=105%, WARN >=100%)

Net Debt (-325.5m) to EBITDA (772.1m) ratio: -0.42 <= 3.0 (WARN <= 3.5)

Current Ratio 2.87 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (72.7m) change vs 12m ago -0.95% (target <= -2.0% for YES)

Gross Margin 35.59% (prev 35.00%; Δ 0.59pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 77.55% (prev 78.26%; Δ -0.71pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 433.6 (EBITDA TTM 772.1m / Interest Expense TTM 1.40m) >= 6 (WARN >= 3)

Altman Z'' 10.49

(A) 0.29 = (Total Current Assets 1.82b - Total Current Liabilities 635.4m) / Total Assets 4.11b

(B) 1.04 = Retained Earnings (Balance) 4.26b / Total Assets 4.11b

warn (B) unusual magnitude: 1.04 — check mapping/units

(D) 3.96 = Book Value of Equity 4.18b / Total Liabilities 1.05b

Total Rating: 10.49 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 71.80

1. Piotroski 6.50pt

2. FCF Yield 1.95%

3. FCF Margin 12.56%

4. Debt/Equity 0.10

5. Debt/Ebitda -0.42

6. ROIC - WACC (= 8.24)%

7. RoE 17.33%

8. Rev. Trend 31.57%

9. EPS Trend -58.35%

What is the price of WST shares?

As of January 15, 2026, the stock is trading at USD 271.83 with a total of 399,600 shares traded.
Over the past week, the price has changed by -3.20%, over one month by -0.01%, over three months by +3.65% and over the past year by -19.70%.

Is WST a buy, sell or hold?

West Pharmaceutical has received a consensus analysts rating of 4.69. Therefore, it is recommended to buy WST.

Strong Buy: 10
Buy: 2
Hold: 1
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the WST price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	345.7	27.2%
Analysts Target Price	345.7	27.2%
ValueRay Target Price	266	-2.1%

WST Fundamental Data Overview January 10, 2026

P/E Trailing = 40.8353
P/E Forward = 37.1747
P/S = 6.5612
P/B = 6.5646
P/EG = 3.5176
Beta = 1.167
Revenue TTM = 3.02b USD
EBIT TTM = 607.0m USD
EBITDA TTM = 772.1m USD
Long Term Debt = 202.7m USD (from longTermDebt, last quarter)
Short Term Debt = 22.9m USD (from shortTermDebt, last quarter)
Debt = 303.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -325.5m USD (from netDebt column, last quarter)
Enterprise Value = 19.48b USD (19.80b + Debt 303.0m - CCE 628.5m)
Interest Coverage Ratio = 433.6 (Ebit TTM 607.0m / Interest Expense TTM 1.40m)
EV/FCF = 51.37x (Enterprise Value 19.48b / FCF TTM 379.1m)
FCF Yield = 1.95% (FCF TTM 379.1m / Enterprise Value 19.48b)
FCF Margin = 12.56% (FCF TTM 379.1m / Revenue TTM 3.02b)
Net Margin = 16.30% (Net Income TTM 491.7m / Revenue TTM 3.02b)
Gross Margin = 35.59% ((Revenue TTM 3.02b - Cost of Revenue TTM 1.94b) / Revenue TTM)
Gross Margin QoQ = 36.49% (prev 35.66%)
Tobins Q-Ratio = 4.74 (Enterprise Value 19.48b / Total Assets 4.11b)
Interest Expense / Debt = 0.03% (Interest Expense 100.0k / Debt 303.0m)
Taxrate = 19.54% (34.0m / 174.0m)
NOPAT = 488.4m (EBIT 607.0m * (1 - 19.54%))
Current Ratio = 2.87 (Total Current Assets 1.82b / Total Current Liabilities 635.4m)
Debt / Equity = 0.10 (Debt 303.0m / totalStockholderEquity, last quarter 3.05b)
Debt / EBITDA = -0.42 (Net Debt -325.5m / EBITDA 772.1m)
Debt / FCF = -0.86 (Net Debt -325.5m / FCF TTM 379.1m)
Total Stockholder Equity = 2.84b (last 4 quarters mean from totalStockholderEquity)
RoA = 12.64% (Net Income 491.7m / Total Assets 4.11b)
RoE = 17.33% (Net Income TTM 491.7m / Total Stockholder Equity 2.84b)
RoCE = 19.97% (EBIT 607.0m / Capital Employed (Equity 2.84b + L.T.Debt 202.7m))
RoIC = 16.07% (NOPAT 488.4m / Invested Capital 3.04b)
WACC = 7.83% (E(19.80b)/V(20.10b) * Re(7.95%) + D(303.0m)/V(20.10b) * Rd(0.03%) * (1-Tc(0.20)))
Discount Rate = 7.95% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.55%
[DCF Debug] Terminal Value 78.21% ; FCFF base≈356.1m ; Y1≈343.8m ; Y5≈339.4m
Fair Price DCF = 90.87 (EV 6.21b - Net Debt -325.5m = Equity 6.54b / Shares 71.9m; r=7.83% [WACC]; 5y FCF grow -4.67% → 2.90% )
EPS Correlation: -58.35 | EPS CAGR: -50.01% | SUE: -4.0 | # QB: 0
Revenue Correlation: 31.57 | Revenue CAGR: 2.66% | SUE: 0.72 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.65 | Chg30d=+0.002 | Revisions Net=+0 | Analysts=10
EPS next Year (2026-12-31): EPS=7.75 | Chg30d=-0.026 | Revisions Net=+2 | Growth EPS=+9.3% | Growth Revenue=+6.5%

Additional Sources for WST Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle